United Therapeutics Co. (UTHR) Shares Bought by WINTON GROUP Ltd

WINTON GROUP Ltd boosted its position in United Therapeutics Co. (NASDAQ:UTHR) by 175.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 92,259 shares of the biotechnology company’s stock after acquiring an additional 58,814 shares during the quarter. WINTON GROUP Ltd owned 0.21% of United Therapeutics worth $11,798,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legacy Financial Advisors Inc. bought a new position in United Therapeutics in the second quarter valued at $107,000. Sun Life Financial INC bought a new position in United Therapeutics in the second quarter valued at $198,000. Unison Advisors LLC bought a new position in United Therapeutics in the third quarter valued at $224,000. Balasa Dinverno & Foltz LLC bought a new position in United Therapeutics in the third quarter valued at $260,000. Finally, Fox Run Management L.L.C. bought a new position in United Therapeutics in the second quarter valued at $269,000. 95.71% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ UTHR opened at $116.60 on Friday. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a 12-month low of $100.57 and a 12-month high of $152.55. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of 10.71, a price-to-earnings-growth ratio of 27.09 and a beta of 1.23.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.23 by ($0.81). The business had revenue of $412.70 million for the quarter, compared to analysts’ expectations of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The business’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.69 earnings per share. Sell-side analysts predict that United Therapeutics Co. will post 14.39 earnings per share for the current fiscal year.

Several analysts have issued reports on UTHR shares. Zacks Investment Research lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Sunday, July 15th. Wedbush upped their price target on shares of United Therapeutics from $234.00 to $253.00 and gave the company an “outperform” rating in a research report on Thursday, August 2nd. HC Wainwright restated a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a research report on Thursday, August 2nd. Barclays restated a “sell” rating and set a $100.00 price target on shares of United Therapeutics in a research report on Thursday, August 2nd. Finally, Cowen restated a “hold” rating and set a $110.00 price target on shares of United Therapeutics in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. United Therapeutics has a consensus rating of “Hold” and a consensus price target of $136.25.

In other news, Director Christopher Causey sold 810 shares of the stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $119.00, for a total transaction of $96,390.00. Following the completion of the sale, the director now directly owns 1,555 shares in the company, valued at $185,045. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard Giltner sold 3,240 shares of the stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,860 shares of company stock valued at $611,161. 8.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Co. (UTHR) Shares Bought by WINTON GROUP Ltd” was originally posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/09/united-therapeutics-co-uthr-shares-bought-by-winton-group-ltd.html.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Story: Ex-Dividend

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply